WHO Raises Alert Over Critical Scarcity of Obesity Injections
Less than 10% of patients eligible to benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its initial advice on the medications.
Given over a billion people worldwide currently living with obesity, it is calling for more widespread and fairer availability to this class of drugs.
Per projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidance affirms that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to broad access to the treatments that can help people shift substantial weight, says the body.
Skinny Jab Scarcity
Even in the present best projected scenario, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, according to the health organization.
The advice urges governments and firms to expand access, by approaches like patent sharing.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so people consume fewer calories.
Individuals usually see weight reduction in the initial weeks of starting on the weekly injections.
Evidence points to people may put most of the weight back on after a year of stopping the treatment, when their usual appetite come back.
Being overweight or obese raises your risk for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, per the health agency.
